1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Lin BioScience, Inc.

Lin BioScience, Inc.

TTPEX:6696
162.50
TWD
-7.50
(-4.41%)
35.20BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.15
-0.28
-0.22
-0.38
-0.24
-0.62
-0.43
-0.92
-0.95
-1.66
- -
Free Cash Flow per Basic Share
-0.48
-0.49
-0.2
-0.35
-0.28
-0.42
-0.53
-1.36
-1.31
-1.77
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.77
0.83
0.61
0.23
1.29
0.76
1.67
2.7
3.61
12.96
12.78
Tangible Book Value per Share
0.59
0.65
0.43
0.06
1.15
0.63
1.52
2.57
3.46
12.82
12.64
Basic Weighted Avg Shares
275
574
623
613
640
703
722
745
786
821
829
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-21,715.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
2
4
4
4
11
18
20
24
- -
Net Income, GAAP
-42
-159
-139
-235
-152
-435
-314
-687
-744
-1,363
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-22,205.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
362
400
263
29
803
349
1,592
3,286
5,196
16,173
16,415
LT Debt
- -
- -
- -
5
2
- -
36
29
18
8
65
Total Equity
478
517
377
143
910
453
1,736
3,429
5,354
25,134
25,561
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-31.98
-30.96
-90.61
-28.81
-59.8
-35.31
-40.76
-29.82
-20.06
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
15
14
28
LT Borrowings
- -
- -
- -
LT Finance Leases
10
8
65
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
827
828
829
Market Capitalization
11,292
32,882
35,200

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
5,337
16,456
16,857
Cash, Cash Equivalents & STI
5,219
16,293
16,597
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
130
283
443
Payables & Accruals
- -
- -
- -
ST Debt
15
14
28
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
151.23%
369.47%
Free Cash Flow
- -
59.9%
41.2%
Net Income, GAAP
- -
73.8%
83.11%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.95
2025
- -
- -
-1.66
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cheng Chi Wang
Full Time Employees
63
Sector
Health technology
Industry
Biotechnology
Address
No. 68, Zhongxiao East Road Taipei TP Taiwan 110
IPO Date
Oct 8, 2018
Website
linbioscience.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Lin BioScience, Inc. (TPEx: 6696) is a clinical-stage biopharmaceutical company that develops innovative small-molecule therapeutics addressing unmet medical needs in oncology, ophthalmology, and metabolic diseases. The company's core pipeline includes LBS-007, a natural non-ATP competitive CDC7 inhibitor in Phase 1/2 trials for relapsed or refractory acute myeloid leukemia, acute lymphocytic leukemia, and solid tumors; LBS-002, an anti-tubulin agent targeting glioblastoma and brain metastases; LBS-008 (tinlarebant), an oral RBP4 antagonist in Phase 3 trials for Stargardt disease and Phase 2/3 for dry age-related macular degeneration; and LBS-009, an oral therapy for non-alcoholic steatohepatitis and type 2 diabetes. LBS-008 and LBS-009 are advanced by its U.S.-listed subsidiary Belite Bio, Inc. (Nasdaq: BLTE), while LBS-007 and LBS-002 are developed in-house. Founded in 2016 and headquartered at No. 68, Zhongxiao East Road, Section 5, Xinyi District, Taipei, Taiwan, the company conducts clinical trials across the U.S., Australia, Taiwan, and other regions. In November 2024, LBS-007 received U.S. FDA Fast Track Designation for acute myeloid leukemia, complementing its prior Orphan Drug Designations for acute myeloid and lymphocytic leukemias; additionally, Belite Bio initiated a Phase 3 trial for LBS-008 in Stargardt disease.